Drug Research

The next-generation biotherapeutics will receive $300 million from Novartis, according to the company. To build a fully integrated, dedicated scientific environment to boost its capabilities and capacity for early technological development of biologics, the multi-year investment will be deployed...

Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the treatment of eosinophilic esophagitis and paediatric eczema, and now the IL-4/IL-13 inhibitor has achieved a...

Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance's long-awaited Botox rival, has officially received FDA approval,...

A group of type 1 antibodies recently made available by Bio-Rad Laboratories are intended to prevent the drug evolcumab from attaching to its target, human proprotein convertase subtilisin/kexin type 9. (PCSK9). These recombinant, sequence-defined antibodies are meant to create...

By demonstrating a massive survival benefit, Keytruda's Keynote-189 study precipitated a turning point in the development of lung cancer medications. Merck & Co. is now providing a five-year review of the data that rendered the PD-1 inhibitor the norm...

The treatment for paediatric patients with severe malaria is being evaluated through research. The first patient has been enrolled in the SEVUSMART study, according to a statement from Modus Therapeutics, a firm that creates therapies for individuals who have significant unmet...

A new variation of the CRISPR-Cas9 gene editing system, according to researchers from the Gladstone Institutes and University of California San Francisco (UCSF), enables the introduction of particularly long DNA sequences to specific locations in the genomes of cells...